Novartis Dirección

Dirección controles de criterios 2/4

El CEO de Novartis es Vas Narasimhan , nombrado en Feb 2018, tiene una permanencia de 6.75 años. compensación anual total es $15.78M, compuesta por 13.7% salario y 86.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.016% de las acciones de la empresa, por valor de R$195.97M. La antigüedad media del equipo directivo y de la junta directiva es de 3.2 años y 8.8 años, respectivamente.

Información clave

Vas Narasimhan

Chief Executive Officer (CEO)

US$15.8m

Compensación total

Porcentaje del salario del CEO	13.7%
Permanencia del CEO	6.8yrs
Participación del CEO	0.02%
Permanencia media de la dirección	3.2yrs
Promedio de permanencia en la Junta Directiva	8.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Vas Narasimhan en comparación con los beneficios de Novartis?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	US$12b
Jun 30 2024	n/a	n/a	US$10b
Mar 31 2024	n/a	n/a	US$9b
Dec 31 2023	US$16m	US$2m	US$9b
Sep 30 2023	n/a	n/a	US$7b
Jun 30 2023	n/a	n/a	US$7b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$12m	US$2m	US$6b
Sep 30 2022	n/a	n/a	US$21b
Jun 30 2022	n/a	n/a	US$22b
Mar 31 2022	n/a	n/a	US$24b
Dec 31 2021	US$12m	US$2m	US$23b
Sep 30 2021	n/a	n/a	US$10b
Jun 30 2021	n/a	n/a	US$9b
Mar 31 2021	n/a	n/a	US$8b
Dec 31 2020	US$12m	US$2m	US$8b
Sep 30 2020	n/a	n/a	US$7b
Jun 30 2020	n/a	n/a	US$7b
Mar 31 2020	n/a	n/a	US$7b
Dec 31 2019	US$12m	US$2m	US$7b
Sep 30 2019	n/a	n/a	US$7b
Jun 30 2019	n/a	n/a	US$7b
Mar 31 2019	n/a	n/a	US$13b
Dec 31 2018	US$10m	US$2m	US$13b
Sep 30 2018	n/a	n/a	US$14b
Jun 30 2018	n/a	n/a	US$14b
Mar 31 2018	n/a	n/a	US$8b
Dec 31 2017	US$5m	US$864k	US$7b

Compensación vs. Mercado: La compensación total de Vas($USD15.78M) está por encima de la media de empresas de tamaño similar en el mercado BR ($USD5.76M).

Compensación vs. Ingresos: La compensación de Vas ha aumentado más de un 20% en el último año.

CEO

Vas Narasimhan (48 yo)

6.8yrs

Permanencia

US$15,778,038

Compensación

Dr. Vasant Narasimhan, also known as Vas, M.D., serves as Chief Executive Officer of Novartis AG at Novartis India Ltd. Dr. Narasimhan has been Chief Executive Officer of Novartis AG since February 1, 2018...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Vasant Narasimhan	Chief Executive Officer	6.8yrs	US$15.78m	0.016% R$ 196.0m
Harry Kirsch	Chief Financial Officer	11.5yrs	US$7.76m	0.019% R$ 226.6m
Victor Bulto	President of US	2.6yrs	US$6.13m	0.0017% R$ 20.2m
Patrick Horber	President of International	less than a year	US$7.95m	0.0014% R$ 16.5m
Steffen Lang	President of Operations	2.6yrs	US$4.17m	0.0077% R$ 91.6m
Paul Penepent	Head of Group Financial Reporting and Accounting	no data	sin datos	sin datos
Sloan Simpson	Global Head of Investor Relations	less than a year	sin datos	sin datos
Klaus Moosmayer	Chief Ethics	5.9yrs	US$2.67m	0.0019% R$ 22.1m
Karen Hale	Chief Legal Officer	3.5yrs	US$4.16m	0.0012% R$ 14.4m
Robert Kowalski	Chief People & Organization Officer	3.2yrs	US$3.45m	0.0011% R$ 12.8m
Etienne Jousseaume	Head of Market Access	no data	sin datos	sin datos
Linda Armstrong	Global Head of Respiratory Development	no data	sin datos	sin datos

3.2yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de N1VS34 se considera experimentado (3.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Sidonie Golombowski-Daffner	Chairperson & President of Advanced Accelerator Applications	no data	sin datos	sin datos
Simon Moroney	Independent Vice Chairman of the Board	4.8yrs	US$546.92k	0.00030% R$ 3.6m
Daniel Vasella	Honorary Chairman	no data	US$3.34m	sin datos
Bridgette Heller	Independent Non-Executive Director	4.8yrs	US$511.25k	0.00031% R$ 3.7m
Joerg Reinhardt	Independent Non-Executive Chairman	11.3yrs	US$4.52m	0.033% R$ 392.2m
François van Houten	Independent Non-Executive Director	7.8yrs	US$469.25k	0.00086% R$ 10.3m
Ton Buechner	Independent Non-Executive Director	8.8yrs	US$504.92k	0.0011% R$ 13.8m
William Winters	Independent Non-Executive Director	11.8yrs	US$428.02k	0.0015% R$ 18.4m
Charles Sawyers	Independent Non-Executive Director	11.8yrs	US$428.02k	0.00087% R$ 10.4m
Patrice Bula	Lead Independent Director	5.8yrs	US$491.97k	0.00056% R$ 6.7m
Nancy Andrews	Independent Non-Executive Director	9.8yrs	US$428.02k	0.00053% R$ 6.3m
Elizabeth Doherty	Independent Non-Executive Director	8.8yrs	US$535.03k	0.00074% R$ 8.9m

8.8yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de N1VS34 se considera experimentada (8.8 años de antigüedad promedio).

Novartis Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Novartis AG, Annual General Meeting, Mar 07, 2025

Recent updates

Novartis' Scemblix® Receives Approval from US Food and Drug Administration

Novartis Raises Earnings Guidance for the Fiscal Year 2024

Novartis Receives Positive CHMP Opinion for Kisqali to Help Reduce Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

Novartis AG, Annual General Meeting, Mar 07, 2025

Alkem Labs Reportedly in Talks to Acquire Novartis India from Its Swiss Parent

Novartis Announces Positive Topline Results from Twice-Yearly Leqvio (Inclisiran) in the Phase III V-Mono Study

Siemens Healthineers Offers to Buy Novartis Molecular Imaging Business

Novartis Receives FDA Accelerated Approval for Fabhalta (iptacopan)

Novartis AG to Report Q4, 2024 Results on Jan 31, 2025

Novartis AG Presents Latest Phase III Fabhalta®? (iptacopan) Data in C3 Glomerulopathy (C3G)

Novartis AG (SWX:NOVN) entered into an agreement to acquire Mariana Oncology, Inc. from Atlas Venture L.P., Access Biotechnology, RA Capital Management, L.P., Deep Track Capital, LP, Forbion Capital Partners B.V. and others for $1.8 billion.

Novartis and Medicines for Malaria Venture Announce Positive Efficacy and Safety Data for A Novel Treatment for Babies

Novartis AG Revise Earnings Guidance for the Year 2024

Novartis' Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market

Novartis Presents Results from Pre-Specified Interim Analysis of the Phase III APPLAUSE-IgAN study of Fabhalta

Novartis Fabhalta Receives Positive CHMP Opinion as First Oral Monotherapy for Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Novartis AG (SWX:NOVN) acquired IFM Due, Inc. from IFM Therapeutics, LLC for approximately $840 million.

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Novartis AG Announces FDA Approves Xolair® (Omalizumab) as First and Only Medicine for Children and Adults with One or More Food Allergies

Novartis Reportedly in Lead to Acquire MorphoSys

Novartis AG Provides Earnings Guidance for the Year 2024

Novartis AG to Report Q1, 2024 Results on Apr 23, 2024

Novartis AG Presents Data from the Phase III NETTER-2 Trial

Novartis Pursuit of Cytokinetics Reportedly Cools

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

Novartis AG Announces Positive Results from the Primary Analysis of ASC4FIRST

Novartis AG (SWX:NOVN) acquired SanReno Therapeutics from Pivotal bioVenture Partners China, Versant Venture Management, LLC, Samsara BioCapital LLC, Frazier Healthcare Partners managed by Frazier Management, L.L.C. and Frazier Life Sciences Management, LP.

Novartis Investigational Iptacopan Phase III Study Demonstrates Clinically Meaningful and Statistically Significant Proteinuria Reduction in Patients with C3 Glomerulopathy (C3G)

Latest Novartis Kisqali(R) Natalee Analysis Reinforces 25% Reduction in Risk of Recurrence Across Broad Population of Patients with Early Breast Cancer

Novartis Receives FDA Approval for Fabhalta (iptacopan) Offering Superior Hemoglobin Improvement in the Absence of Transfusions as the First Oral Monotherapy for Adults with PNH

Novartis AG to Report Q4, 2023 Results on Jan 31, 2024

Novartis Announces New Positive Data from the Phase III REMIX-1 and REMIX-2 Studies Investigating Remibrutinib

Novartis Announces US Food and Drug Administration Approves Cosentyx® to Treat Moderate to Severe Hidradenitis Suppurativa in Adults

Novartis Announces Positive Topline Results from the Interim Analysis of the Ongoing Pivotal Phase III ALIGN Study

Novartis AG Announces Impairment Charges for the Third Quarter of 2023

Novartis AG Raises Earnings Guidance for the Fiscal Year 2023

Novartis Kisqali Natalee Analysis Confirms Consistent Reduction in Risk of Recurrence Across Key Sub Groups of Patients with Early Breast Cancer

FDA Approves Novartis Cosentyx® as First Intravenous (Iv) Formulation Interleukin-17A Antagonist for Rheumatic Diseases

Novartis to Present New Oncology Data at ESMO 2023 Demonstrating Practice-Changing Innovation in Advanced Prostate and Early Breast Cancer

Novartis AG completed the Spin-Off of Sandoz Group AG (SWX:SDZ).

Bausch & Lomb Ireland completed the acquisition of ophthalmology assets of Novartis AG from Novartis AG for $2.5 billion.

Sandoz, Novartis Division, Receives European Commission Approval for Tyruko (Natalizumab), First and Only Biosimilar for Multiple Sclerosis in Europe

Novartis Radioligand Therapy Lutathera® Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival in First Line Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Novartis AG Issues Voluntary Nationwide Recall of One Lot of Sandimmune Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad